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Abstract. All Plasmodium cases have declined over the last decade in northwestern Thailand along the Myanmar
border. During this time, Plasmodium vivax has replaced Plasmodium falciparum as the dominant species. The decline in
P. falciparum has been shadowed by a coincidental but delayed decline in P. vivax cases. This may be due to early
detection and artemisinin-based therapy, species-specific diagnostics, and bed net usage all of which reduce malaria
transmission but not P. vivax relapse. In the absence of widespread primaquine use for radical cure against P. vivax
hypnozoites, the decline inP. vivaxmaybe explained by decreased hypnozoite activation ofP. vivax relapses triggered by
P. falciparum. The observed trends in this region suggest a beneficial effect of decreased P. falciparum transmission on
P. vivax incidence, but elimination of P. vivax in a timely manner likely requires radical cure.
INTRODUCTION
Malaria has decreased in the Greater Mekong Subregion
(GMS) over the last decade. The WHO estimates that from
2012 to 2015, malaria cases declined by 54% and malaria-
related mortality by 84% in this region. All GMS nations have
drafted plans for malaria elimination by 2030.1 Because of the
emergence of artemisinin-resistant parasites Plasmodium
falciparum rather than Plasmodium vivax has been the focus
of elimination. Plasmodium vivax remains a major contributor
to morbidity largely because of relapses (as high as 80% in
northwest Thailand).2 Treating relapses (radical cure) requires
completingaprolongedprimaquinecourse (7–14days), leading
to decreased adherence.Daily primaquinedoses (0.25–0.5mg/
kg/day) needed for radical cure are contraindicated in persons
with glucose-6-phosphate dehydrogenase (G6PD) deficiency
becauseof hemolytic risk.3WhenG6PD testing is not available,
primaquine prescription is less likely. A weekly (for 8 weeks)
regimen is recommended forG6PD-deficient individuals,which
also limits adherence. Currently, primaquine is contraindicated
during pregnancy and lactation.3 Consequently, the drug is
often not prescribed, relapses are not prevented, and clinical
infections recur after schizonticidal treatment.
Plasmodium falciparum malaria has decreased along the
Thailand–Myanmar border over the last decade.4 Without
widespread radical cure, a different patternmight be expected
for P. vivax. Here, we report longitudinal trends in passively
detected P. vivax infections in medical clinics along the
Thailand–Myanmar border for a period spanning 22 years.
METHODS AND RESULTS
Shoklo Malaria Research Unit (SMRU) operates clinics lo-
cated in Thailand along theMoei River, which forms the border
with Myanmar. The unit has field-based medical clinics, situ-
ated 30–120 km outside Mae Sot, Thailand, serving refugee
and migrant (mostly unregistered) border populations. The
refugee clinic operated from 1986 to 2016. The first migrant
clinic was opened in 1998, second in 1999, and two additional
clinics were opened in 2004–2005.
Malaria transmission in this area is low, unstable, and sea-
sonal.5 The dominant species are P. falciparum and P. vivax,
and Plasmodium malariae and Plasmodium ovale are un-
common. In patients with a fever history, a malaria smear was
performed routinely in the refugee clinic, whereas in the mi-
grant clinics malaria rapid diagnostic tests (RDTs) were also
performed. Malaria smears in the migrant clinics were per-
formed systematically in children aged < 5 years and during a
one-week period each month (called “smear week”).6 Before
March 2010, the RDTs that were used diagnosed only
P. falciparum soP. vivaxwasaclinical diagnosis (i.e., fever and
RDT negative) during the non “smear weeks”. When newer
RDTs were used, all P. vivax diagnoses were confirmatory
(RDTs or malaria smear). Malaria microscopy was per-
formed by trained laboratory technicians. Standardized
quality control for malaria smear and RDT reading was
conducted routinely.
At SMRU, mefloquine–artesunate was the first-line
treatment for P. falciparum and mixed P. falciparum infec-
tions from 1994 until June 2012 when it was changed to
dihydroartemisinin–piperaquine plus gametocytocidal single-
dose primaquine. Chloroquine has remained efficacious
against P. vivax. After 2010, routine radical cure for P. vivax
was implemented, but only under direct supervision, resulting
in<10%ofpatientswithP. vivax treatedwithprimaquine.Until
2017, there were no targeted radical curative interventions
in the population. However, from 2010 to 2014, a series of
P. vivax studies were performed and primaquine was pre-
scribed to ∼1,200 participants. A P. falciparum elimination
campaign in community-basedmalaria clinics using standard
artemisinin-based therapy (ACTs) and single-dose prima-
quine began in 2014 in Kayin State, Myanmar, covering areas
opposing Tak Province. In these community-based malaria
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clinics, some overlapping the SMRU catchment area, radical
cure for P. vivax was not prescribed.7,8
For this analysis, aggregated anonymized data from
monthly reports on nonpregnant patients with P. falciparum
and P. vivax malaria diagnosed in the SMRU medical clinics
from July 1995 to December 2016 in refugees and November
1998 to December 2016 in migrants (before universal prima-
quine administration) were included. Mixed infections were
attributed to both P. falciparum and P. vivax cases. In years
with clinical P. vivax diagnosis, the annual caseload was ad-
justed by the proportion of P. vivax cases detected during the
“smear weeks” of the same year. Descriptive statistics were
used for P. vivax and P. falciparum cases by year, age (grou-
ped every 5 years until 39 years, then all ³ 40 years), gender,
and status (migrant or refugee). Poisson regressions were
used to test for differences in trends in cases over time by age-
group, gender, and status. Then the data were stratified by
gender with an interaction term between year and age-group
to detect changing patterns in the distribution of cases across
the lifespan, over time.
Overall, the number of malaria cases decreased (Figure 1).
Increases in 1999 and 2005 coincided with opening new mi-
grant clinics andpeaked in2006.By theendof 2010, therewas
a 3-fold decrease in P. falciparum cases (from 2006 to 2010,
21,008 to 6,196 cases, respectively). Plasmodium vivax cases
decreased nearly 2-fold, but the decline was delayed (from
2006 to 2011, 11,914 to 6,642 cases, respectively) in com-
parison with P. falciparum (Figure 1). During this time, P. vivax
transitioned to become the dominant species6 (Figure 2). After
2010, malaria positivity continued to decrease for both spe-
cies. This occurred alongside a∼50%decline in consultations
for non-malarial fever from 2011 to 2014 and which plateaued
after 2014. In 2014, 2015, and 2016, approximately 3,400,
6,600, and 6,200 cases, respectively, of P. vivax were treated
by the community-based malaria clinics; many located a few
days travel inside Myanmar. Migrants had a 50% higher risk
for malaria (incidence risk ratio (IRR) 1.5, 95% CI: 1.40–1.67;
P < 0.001) than refugees. In both migrant and refugee clinics,
the greatest declines in malaria incidence risk occurred in the
< 10 year age-groups (Figure 3) and nearly an 80% reduction
for P. falciparum (2006–2010) and 70% reduction for P. vivax
(2006–2011) in the 0–4 years group. Females had a 56%
lower incidence risk of malaria per year (IRR 0.44, 95% CI:
0.40–0.49;P<0.001) (Supplemental Table 1).Whenassessing
IRR differences between gender by age-group, males aged
³ 10 years had a higher incidence risk of P. falciparum and
P. vivaxmalaria each year. This risk difference ended with the
³ 40 year age-group forP. vivax but persisted forP. falciparum
(Supplemental Tables 2 and 3). The overall trends and risks
FIGURE 1. Number of cases of Plasmodium falciparum and Plasmodium vivax from 1995 to 2016 in the refugee andmigrant clinics. Plasmodium
falciparum is indicated in blue andPlasmodium vivax in red. CQ = chloroquine; DP = dihydroartemisinin piperaquine; MAS3 =mefloquine 25mg/kg
total dose plus artesunate 4 mg/kg/day for 3 days; PQ DOT = primaquine directly observed treatment (in patients who agreed to follow up); RDT =
rapid diagnostic test.
FIGURE 2. Percentage of Plasmodium falciparum and Plasmodium
vivax for each year from 1998 to 2016 in migrant clinics and 1995 to
2016 in refugee clinics.
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were similar when the analysis was performed with and with-
out correcting for clinical P. vivax diagnosis.
DISCUSSION
As P. falciparum cases have decreased, a coincidental and
delayed decrease in P. vivax has followed.9,10 Similar to other
parts of Southeast Asia where P. falciparum is being elimi-
nated, P. vivax becomes dominant, although not all countries
report consistent declines in P. vivax caseload.11 Early di-
agnosis, efficacious ACTs, and single-dose primaquine con-
tribute to lower P. falciparum transmission12,13; however, in
the absence of widespread radical cure, the explanation for
declining P. vivax is less clear.
The observed trend was not affected by the introduction of
pan-malaria RDTs in 2010. It is also unlikely that the provision
of radical cure to < 10% of P. vivax patients would drastically
reduce the incidence risk of P. vivax as demonstrated here. A
more probable explanation to the decreasingP. vivax cases at
SMRU medical clinics is the opening of more than 1,200
community-based malaria clinics along the border, where
similar shifts have been reported14; however, radical cure for
P. vivax is not given there. It is also possible that reducing
P. falciparum transmission reduces P. vivax infections mainly
by decreasing relapse activation.15,16
Other factors potentially contribute to the decline of
P. vivax. From2009 to 2016,more than 280,000 insecticide-
treated bed nets were distributed in the area, but their ef-
fectiveness is decreased by early evening mosquito biting
behavior.17 Broad changes in the landscape along the in-
ternational border, including deforestation, industrial agri-
culture, and urbanization,18,19 may contribute to an overall
decrease in malaria, although a direct association cannot be
made with these data. Gametocytocidal treatment with ACTs
may contribute to decreased P. vivax transmission20; how-
ever, mixed infections are uncommon. A series of clinical
studies (2010–2014) using radical curative primaquine may
have contributed to decreased P. vivax transmission. This
does not explain the longitudinal trends reported here or from
the community clinics where no P. vivax studies are being
conducted.8 Still, migrants and adult males remain at highest
risk for P. vivax infection because of environmental and
occupational exposure. Refugees (unless migratory) are
confined to semi-urban camps where there is no malaria
transmission. More detailed analyses stratified by age and
gender are not possible with the available data.
In combination, species-specific diagnostics, bed nets,
efficacious schizonticidal treatment, and comprehensive
radical cure would presumably reduce the incidence of
P. vivax at the same rate asP. falciparum. Without widespread
radical cure, we postulate that the coincidental decline in
P. vivax and its delay relative to P. falciparum in this area are
due to decreased activation of P. vivax hypnozoites from re-
duced P. falciparum transmission.15,16 As the region ap-
proaches P. falciparum elimination, it is clear that P. vivax also
requires a program for elimination. The trends reported here
are promising, although radical cure will likely be necessary to
completely eliminate P. vivax from this region.
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